At a glance
- Originator Pennwalt Corporation
- Class Antirheumatics; Immunotherapies; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 25 Oct 1994 No-Development-Reported for Rheumatoid arthritis in USA (PO)